Scott Burrows is the Chief Financial Officer at SPYRE THERAPEUTICS INC, a biopharmaceutical company focused on developing novel therapies for inflammatory diseases. With over 20 years of experience in finance and strategic planning within the healthcare industry, Scott has become a pivotal figure in guiding the financial strategy and growth of Spyre Therapeutics. Prior to joining Spyre, he held significant roles at several leading pharmaceutical companies, including positions at Bristol Myers Squibb and Novartis, where he honed his expertise in financial management and corporate development. At Bristol Myers Squibb, Scott was instrumental in leading the finance team through a period of significant growth and acquisitions, contributing to the company's robust financial performance. His tenure at Novartis saw him spearheading strategic financial initiatives that enhanced the company's operational efficiency and market position. These experiences have equipped him with a deep understanding of the complexities of the biopharmaceutical sector, making him an invaluable asset to Spyre Therapeutics. As CFO at Spyre Therapeutics, Scott Burrows is responsible for overseeing all aspects of the company's financial operations, from budgeting and forecasting to investor relations and financial reporting. His strategic vision and leadership are crucial in navigating the challenges of drug development and commercialization. Under his guidance, Spyre Therapeutics continues to strengthen its financial foundation, ensuring the company is well-positioned to advance its innovative pipeline and deliver transformative treatments to patients suffering from inflammatory diseases.